Bone Biologics Corp Announces 2026 Milestones Progress (8-K)

What Happened
On July 23, 2026, Bone Biologics Corporation (BBLG) filed a Form 8-K (Item 7.01) to disclose a press release summarizing progress on its 2026 corporate, scientific and operational priorities. The press release is furnished as Exhibit 99.1 to the report.

Key Details

• Filing date: July 23, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Exhibit furnished: Press Release dated July 23, 2026 (Exhibit 99.1).
• Additional exhibit: Cover Page Interactive Data File (Inline XBRL) included as Exhibit 104.
• This filing is a Regulation FD disclosure (informational); it is not an earnings (Item 2.02), executive change (Item 5.02), merger (Item 1.01) or bankruptcy (Item 1.03) report.

Why It Matters
The company publicly disclosed progress on its 2026 priorities, giving all investors the same update under Regulation FD. Investors should read the Exhibit 99.1 press release for specifics on program and operational milestones, as those details could influence sentiment and expectations about Bone Biologics’ development progress. Monitor subsequent SEC filings and company releases for any material financial results or changes in strategy.